Sector News

Teva inks trailblazing cannabis pact with Israel's Syqe Medical

November 28, 2016
Life sciences

Teva has struck a new marketing agreement, and it’s one that’ll help the Israeli drugmaker blaze a new trail in the drug industry.

The pharma has inked a pact that will make it the only distributor in Israel of local company Syqe Medical’s cannabis inhaler, the companies said Monday, without disclosing any financial data on the agreement. Teva will also help Syqe set up a support and instruction team of nurses for patients and healthcare providers.

As of this year, Israel boasted about 26,000 medical cannabis consumption licenses—a figure that’s expected to double by 2018, Israeli newspaper Globes reports. And with licensed patients spending an average $1,000 per month on cannabis, the revenue potential is there for Teva if the company can get the inhaler selling.

Meanwhile, the inhaler fits in with Teva’s pain product portfolio; as Avinoam Sapir, Teva Israel’s CEO, told Globes, and the company “entered the field of medical cannabis out of its deep commitment to pain patients.” For Teva, pain represents a key therapeutic area that—along with other core fields such as neurodegenerative and respiratory—CEO Erez Vigodman said he’d look to boost following the company’s $40.5 billion acquisition of Allergan’s generics unit.

Another of Teva’s recent pain partnerships has already hit a sour note, though. In October, less than one month after Teva signed on to help develop and commercialize Regeneron NGF antibody fasinumab—an agreement that saw it fork over $250 million upfront—the FDA put a clinical hold on the prospect, prompting Leerink Partners analyst Geoffrey Porges to reduce the med’s probability of success to 0% in his models.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach